BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/12/2021 5:45:28 AM | Browse: 793 | Download: 1852
 |
Received |
|
2021-01-21 10:46 |
|
Peer-Review Started |
|
2021-01-21 10:46 |
|
First Decision by Editorial Office Director |
|
2021-03-16 06:40 |
|
Return for Revision |
|
2021-03-16 06:40 |
|
Revised |
|
2021-04-05 03:44 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2021-06-04 08:32 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2021-06-04 09:06 |
|
Articles in Press |
|
2021-06-04 09:06 |
|
Edit the Manuscript by Language Editor |
|
2021-06-15 00:16 |
|
Typeset the Manuscript |
|
2021-07-06 00:52 |
|
Publish the Manuscript Online |
|
2021-07-12 05:45 |
| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medicine, Research & Experimental |
| Manuscript Type |
Basic Study |
| Article Title |
Possible drug for type 2 diabetes-decarboxylated osteocalcin triggers glucose uptake in MG63 cells
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Shi Jin, Xiao-Cen Chang, Jing Wen, Jing Yang, Na Ao, Ke-Ying Zhang, Lin-Na Suo and Jian Du |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Provincial Science and Technology Department Natural Fund Guidance Project |
2019-ZD-0774 |
| National Natural Science Foundation of China |
81470998 |
| Liaoning Ministry of Education |
LQNK201715 |
| Liaoning Provincial Doctor Start up Fund |
20180540008 |
|
| Corresponding Author |
Jian Du, PhD, Professor, Department of Endocrinology, The Fourth Affiliated Hospital of China Medical University, No. 4 Chongshan Road, Huanggu District, Shenyang 110032, Liaoning Province, China. dujian_1962@163.com |
| Key Words |
Decarboxylated osteocalcin; Osteoblast; Glucose uptake; Glucose transporter 1; Type 2 diabetes |
| Core Tip |
Uncarboxylated osteocalcin (GluOC) has been reported to improve glucose metabolism and prevent type 2 diabetes. GluOC can increase the glucose uptake in a variety of cells. In this study, MG63 cells were treated with different concentrations of decarboxylated osteocalcin (dcOC) for 1 h and 72 h to observe the changes in glucose uptake, proliferation and alkaline phosphatase (ALP) activity, as well as possible signaling pathway. Short- or long-term intervention with dcOC in vitro can increase glucose uptake and promote the proliferation and ALP activity of MG63 cells. This effect may occur through the PI3K/Akt, hypoxia-inducible factor 1 alpha and glucose transporter 1 signaling factors. |
| Publish Date |
2021-07-12 05:45 |
| Citation |
Jin S, Chang XC, Wen J, Yang J, Ao N, Zhang KY, Suo LN, Du J. Possible drug for type 2 diabetes-decarboxylated osteocalcin triggers glucose uptake in MG63 cells. World J Diabetes 2021; 12(7): 1102-1115 |
| URL |
https://www.wjgnet.com/1948-9358/full/v12/i7/1102.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v12.i7.1102 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
